从基础胰岛素研发探讨血糖管理的优化  

Inquiring into the Optimization of Blood Glucose Management from the Research and Development of Basal Insulin

作　　者：曾龙驿[1] ZENG Longyi(The Third Affiliated Hospital,SUN YAT-SEN University,Guangzhou Guangdong 510630,China)

机构地区：[1]中山大学附属第三医院,广东广州510630

出　　处：《药品评价》2021年第24期1477-1480,共4页Drug Evaluation

摘　　要：20世纪40年代,人们通过精蛋白和锌等物质对胰岛素进行修饰,开启了基础胰岛素研发的光辉时代。基础胰岛素的研发以追求模拟机体自身的胰岛素分泌模式为目标,希望达到平坦、稳定、无峰、持续作用、低血糖风险低的临床降糖需求。从中性鱼精蛋白锌胰岛素(neutral protamine hagedorn,NPH)到基础胰岛素类似物,再到新一代基础胰岛素类似物——德谷胰岛素、甘精胰岛素U300,每一次的研发与创新,都突破了原有的局限性,为患者提供更平稳、更便捷的治疗方案。本研究将回顾基础胰岛素研发的百年传奇,以探讨血糖管理方案不断优化之路。In the 1940s,insulin was modified by additives such as protamine and zinc,the glorious era of basal insulin research opened.Simulated the physiological secretory pattern has long been pursued by developers,hoping to achieve flat,stable,no-peak and continuous management of blood glucose,as well as control the risk of hypoglycemia.From NPH to basic insulin analogues,and then to the new generation of basic insulin analogues-degludec,insulin glargine 300 U,every step of research and innovation broke through the original technical limitations and provided patients with more stable and convenient treatment.This reserch reviewed the centennial legend of basic insulin research and development to explore the way of continuous optimization of blood glucose management.

关 键 词：糖尿病 2型 血糖管理 平稳降糖 基础胰岛素类似物 

分 类 号：R587.1[医药卫生—内分泌]